162 related articles for article (PubMed ID: 37309193)
41. Efficacy and safety of HIP1601 (dual delayed-release esomeprazole) 40 mg in erosive esophagitis compared to HGP1705 (delayed-release esomeprazole) 40 mg: a multicenter, randomized, double-blind, non-inferiority study.
Lim H; Park JK; Chung H; Lee SH; Park JM; Park JH; Kim GH; Shin SK; Hong SJ; Lee KJ; Park MI; Jung HK; Kim HS; Sung JK; Jeon SW; Choi SC; Moon JS; Kim N; Park JJ; Hong SH; Kim NY; Jung HY
BMC Gastroenterol; 2023 Dec; 23(1):447. PubMed ID: 38110901
[TBL] [Abstract][Full Text] [Related]
42. Choice of Acid Suppressant Therapy and Long-Term Graft Outcomes After Kidney Transplantation.
January SE; Progar K; Nesselhauf NM; Hagopian JC; Malone AF
Pharmacotherapy; 2020 Nov; 40(11):1082-1088. PubMed ID: 33037663
[TBL] [Abstract][Full Text] [Related]
43. Concomitant Administration of a Histamine2 Receptor Antagonist and Proton Pump Inhibitor Enhances Gastric Acid Suppression.
Abdul-Hussein M; Freeman J; Castell D
Pharmacotherapy; 2015 Dec; 35(12):1124-9. PubMed ID: 26621819
[TBL] [Abstract][Full Text] [Related]
44. Does long-term medication with a proton pump inhibitor induce a tolerance to H2 receptor antagonist?
Hashimoto H; Kushikata T; Kudo M; Hirota K
J Gastroenterol; 2007 Apr; 42(4):275-8. PubMed ID: 17464455
[TBL] [Abstract][Full Text] [Related]
45. A randomized, double-blind, placebo-controlled clinical study of the histamine H2-receptor antagonist famotidine in Japanese patients with nonerosive reflux disease.
Hongo M; Kinoshita Y; Haruma K
J Gastroenterol; 2008; 43(6):448-56. PubMed ID: 18600389
[TBL] [Abstract][Full Text] [Related]
46. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease.
van Pinxteren B; Numans ME; Bonis PA; Lau J
Cochrane Database Syst Rev; 2000; (2):CD002095. PubMed ID: 10796857
[TBL] [Abstract][Full Text] [Related]
47. Effect of a proton pump inhibitor or an H2-receptor antagonist on prevention of bleeding from ulcer after endoscopic submucosal dissection of early gastric cancer: a prospective randomized controlled trial.
Uedo N; Takeuchi Y; Yamada T; Ishihara R; Ogiyama H; Yamamoto S; Kato M; Tatsumi K; Masuda E; Tamai C; Yamamoto S; Higashino K; Iishi H; Tatsuta M
Am J Gastroenterol; 2007 Aug; 102(8):1610-6. PubMed ID: 17403076
[TBL] [Abstract][Full Text] [Related]
48. Comparative risk of incidence and clinical outcomes of COVID-19 among proton pump inhibitor and histamine-2 receptor antagonist short-term users: a nationwide retrospective cohort study.
Park J; You SC; Cho J; Park CH; Shin WG; Park RW; In Seo S
BMC Pharmacol Toxicol; 2022 Jan; 23(1):9. PubMed ID: 35039078
[TBL] [Abstract][Full Text] [Related]
49. Proton pump inhibitors and hypomagnesemia in the general population: a population-based cohort study.
Kieboom BC; Kiefte-de Jong JC; Eijgelsheim M; Franco OH; Kuipers EJ; Hofman A; Zietse R; Stricker BH; Hoorn EJ
Am J Kidney Dis; 2015 Nov; 66(5):775-82. PubMed ID: 26123862
[TBL] [Abstract][Full Text] [Related]
50. Chinese herbal compound prescriptions combined with Chinese medicine powder based on traditional Chinese medicine syndrome differentiation for treatment of chronic atrophic gastritis with erosion: a multi-center, randomized, positive-controlled clinical trial.
Zhang T; Zhang B; Xu J; Ren S; Huang S; Shi Z; Guo S; Bian L; Wang P; Wang F; Cai Y; Tang X
Chin Med; 2022 Dec; 17(1):142. PubMed ID: 36550503
[TBL] [Abstract][Full Text] [Related]
51. [Proton pump inhibitor H2 receptor antagonist].
Shiotani A; Kamada T; Kusunoki H; Manabe N; Haruma K
Nihon Rinsho; 2011 Jun; 69(6):1032-8. PubMed ID: 21688623
[TBL] [Abstract][Full Text] [Related]
52. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
53. A Randomized, Double-Blind, Active-Control, Noninferiority, Multicenter, Phase 4 Study to Evaluate the Efficacy and Safety of Esomeprazole/Sodium Bicarbonate 20/800 mg in Patients with Nonerosive Gastroesophageal Reflux Disease.
Park SH; Lee KN; Lee OY; Choi MG; Kim JH; Sung IK; Jang JY; Park KS; Chun HJ; Kim EY; Lee JK; Jang JS; Kim GH; Hong SJ; Lee YC; Choi SC; Kim HS; Kim TO; Baik GH; Jeon YC
Gut Liver; 2023 Mar; 17(2):226-233. PubMed ID: 35730245
[TBL] [Abstract][Full Text] [Related]
54. Effect of Stress Ulcer Prophylaxis With Proton Pump Inhibitors vs Histamine-2 Receptor Blockers on In-Hospital Mortality Among ICU Patients Receiving Invasive Mechanical Ventilation: The PEPTIC Randomized Clinical Trial.
; Young PJ; Bagshaw SM; Forbes AB; Nichol AD; Wright SE; Bailey M; Bellomo R; Beasley R; Brickell K; Eastwood GM; Gattas DJ; van Haren F; Litton E; Mackle DM; McArthur CJ; McGuinness SP; Mouncey PR; Navarra L; Opgenorth D; Pilcher D; Saxena MK; Webb SA; Wiley D; Rowan KM
JAMA; 2020 Feb; 323(7):616-626. PubMed ID: 31950977
[TBL] [Abstract][Full Text] [Related]
55. Impact of concomitant acid suppressive therapy on pazopanib efficacy and dose reductions in patients with metastatic renal cell carcinoma.
Van De Sijpe G; Beuselinck B; Van Nieuwenhuyse T; Poncelet R; Bechter O; Albersen M; Roussel E; Baldewijns M; Tack J; Spriet I
Eur J Clin Pharmacol; 2020 Sep; 76(9):1273-1280. PubMed ID: 32474662
[TBL] [Abstract][Full Text] [Related]
56. Effect of proton pomp inhibitor (PPI : Rabeprazole) on reflux esophagitis after endoscopic injection sclerotherapy (EIS), a randomized control study (24 hour-pH monitoring).
Akahoshi T; Kawanaka H; Tomikawa M; Saeki H; Uchiyama H; Ikeda T; Shirabe K; Hashizume M; Maehara Y
Fukuoka Igaku Zasshi; 2013 Dec; 104(12):483-9. PubMed ID: 24693675
[TBL] [Abstract][Full Text] [Related]
57. Randomized clinical trial: A double-blind, proof-of-concept, phase 2 study evaluating the efficacy and safety of vonoprazan 20 or 40 mg versus esomeprazole 40 mg in patients with symptomatic gastro-esophageal reflux disease and partial response to a healing dose of a proton-pump inhibitor.
Tack J; Vladimirov B; Horny I; Chong CF; Eisner J; Czerniak R; Takanami Y
Neurogastroenterol Motil; 2023 Jan; 35(1):e14468. PubMed ID: 36178335
[TBL] [Abstract][Full Text] [Related]
58. Effects of Histamine 2-receptor Antagonists and Proton Pump Inhibitors on the Pharmacokinetics of Gefitinib in Patients With Non-small-cell Lung Cancer.
Yokota H; Sato K; Okuda Y; Kobayashi H; Takeda M; Asano M; Ito H; Miura M
Clin Lung Cancer; 2017 Nov; 18(6):e433-e439. PubMed ID: 28579188
[TBL] [Abstract][Full Text] [Related]
59. Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis.
Harris RA; Kuppermann M; Richter JE
Am J Gastroenterol; 1997 Dec; 92(12):2179-87. PubMed ID: 9399748
[TBL] [Abstract][Full Text] [Related]
60. Renal Transplant Acute Rejection with Lower Mycophenolate Mofetil Dosing and Proton Pump Inhibitors or Histamine-2 Receptor Antagonists.
Patel KS; Stephany BR; Barnes JF; Bauer SR; Spinner ML
Pharmacotherapy; 2017 Dec; 37(12):1507-1515. PubMed ID: 28976570
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
